Hatteras Venture Partners related stories
All articles and analysis
Hatteras Venture Partners raises $150mView the latest capital raises
- Hatteras raises over $150 mln for fifth venture fund
Hatteras Venture Partners has closed its fifth venture fund at over $150 million. Hatteras makes seed and early-stage investments in the human medicine life sciences.
IPO Profiles: Six venture-backed companies went IPO in JuneTwilio's debut sparks hope that more tech IPOs are forthcoming
Lumira Capital joins G1 Therapeutics' $47 mln Series C roundG1 Therapeutics Inc has raised US$47 million in a Series C financing. The round was led by Cormorant Asset Management with participation from new and existing investors, including Canadian life sciences venture capital firm Lumira Capital. Lumira also invested in the company's Series B round /canada/2015/2/lumira-capital-invests-in-33-mln-series-b-funding-of-g1-therapeutics/ in early 2015. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a developer of novel, small-molecule therapies that help address unmet needs in people with cancer. It plans to use funds raised to advance the clinical development of its lead drug candidate and compound, and grow its pipeline in multiple oncology indications.
- Lumira Capital joins G1 Therapeutics' $47 mln Series C round
G1 Therapeutics Inc has raised US$47 million in a Series C financing. The round was led by Cormorant Asset Management with participation from new and existing investors, including Canadian life sciences venture capital firm Lumira Capital. Lumira also invested in the company's Series B round /canada/2015/2/lumira-capital-invests-in-33-mln-series-b-funding-of-g1-therapeutics/ in early 2015. Based in Research Triangle Park, North Carolina, G1 Therapeutics is a developer of novel, small-molecule therapies that help address unmet needs in people with cancer. It plans to use funds raised to advance the clinical development of its lead drug candidate and compound, and grow its pipeline in multiple oncology indications.
- Bivarus raises $2 mln
Bivarus said Tuesday it raised $2 million in a round of funding co-led by Hatteras Venture Partners and existing investor Excelerate Health Ventures. Also participating were NueCura Partners and Boston Millennia Partners. Durham, North Carolina-based Bivarus is an analytics company.
- Bioclinica acquires VC-backed Clinverse
Bioclinica has acquired Durham, North Carolina-based Clinverse, a provider of automated financial management technology solutions for clinical trials. No financial terms were disclosed. Clinverse's backers included Edison Partners and Hatteras Venture Partners.
- Drug maker Valeant appoints Schiller as interim CEO
Drug maker Valeant Pharmaceuticals International Inc has named Howard B. Schiller as interim CEO. The appointment is effective immediately. Schiller is Valeant's former chief financial officer. Prior to joining Valeant, Schiller worked at Goldman Sachs where he served as chief operating officer for the company's investment banking division. Valeant's current CEO J. Michael Pearson is on a medical leave of absence.
- ORIG3N raises $12.5 mln
ORIG3N Inc. said Wednesday that it closed a $12.5 million Series A financing co-led by Hatteras Venture Partners and Syno Capital. Also participating in the round was new investor, DEFTA Partners, and existing investors, Harris & Harris Group Inc., LabCorp, MGC Venture Partners and KTB-KORUS Fund. ORIG3N is a biotechnology company that is developing treatments for rare and genetically inherited diseases.
- Qvella scores $20 mln Series A
Canadian molecular diagnostics company Qvella has secured $20 million in Series A funding. RA Capital Management and Whitecap Venture Partners led the round with participation from other investors that included Hatteras Venture Partners and Sands Capital Ventures. According to the company, the capital infusion will be used for personnel hiring and product development.